Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation of T cells. The growing prevalence of autoimmune ...

Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is pleased to announce exciting new data from its Phase ...

Imugene is tapping the market for up to $35 million, while Clever Culture Systems and Compumedics are soaring on positive ...

Objective Alcoholic hepatitis (AH) reflects acute exacerbation of alcoholic liver disease (ALD) and is a growing healthcare burden worldwide. Interleukin-11 (IL-11) is a profibrotic, proinflammatory ...

A genetically diverse mouse model allowed researchers to identify genes that promote the success of immune checkpoint ...

Nurix Therapeutics shows strong BTK degrader data and key pharma ties, with risks but solid long-term potential. Find out why ...

Background Ventilator-associated pneumonia (VAP) is the most commonly fatal nosocomial infection. Clinical diagnosis of VAP remains notoriously inaccurate. The hypothesis was tested that significantly ...

Pacira BioSciences Inc. (NASDAQ:PCRX) is one of the most undervalued small-cap stocks to buy according to analysts. On June ...

Sarilumab treatment with a rapid glucocorticoid taper in relapsing polymyalgia rheumatica shows greater improvements in ...

The trial is spearheaded by Dr Jonathan Hernandez, the surgical oncology section chief of the National Cancer Institute.

Explore the rise and market race of anti-IL23p19 therapies in Inflammatory Bowel Disease (IBD), specifically Ulcerative Colitis (UC). Stay informed on the latest advancements and treatment options.

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study.